[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598100":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":43,"collaborators":45,"id":48,"slug":20,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":20,"enrollmentInfo":57,"targetDuration":20,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":69,"whyStopped":20,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Besancon","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with severe acute flare Hurley stage III HS","EXPERIMENTAL","These patients present with refractory severe HS (Hurley stage III) flare treated with a transfusion of plasma containing high titre anti-IFN-1 auto-Antibodies.",[13],"Biological: Plasma with neutralizing autoantibodies to Type I Interferons",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Plasma with neutralizing autoantibodies to Type I Interferons","Transfusion of one unit of plasma containing high titre anti-IFN-1 autoantibodies",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Charline Vauchy, PhD.","CONTACT","+33381218875","cvauchy@chu-besancon.fr",[28],{"facility":29,"status":20,"city":30,"state":20,"zip":31,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"CHU Besançon","Besançon","25000","France",{"type":34,"coordinates":35},"Point",[36,37],6.01815,47.24878,{"lat":37,"lon":36},[40],{"name":41,"role":42,"phone":20,"phoneExt":20,"email":20},"François Aubin, Prof.","PRINCIPAL_INVESTIGATOR",{"type":44,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[46],{"name":47,"class":6},"Etablissement Français du Sang","100598100",false,"NCT07067099","Neutralizing Interferon Type 1 in Hidradenitis Suppurativa","Use of Plasma With Neutralizing Autoantibodies to Type I Interferons in Patients With Severe Refractory Flare-up of Hidradenitis Suppurativa","NIHS-I","Inclusion Criteria:\n\n* Men and women aged over 18\n* Patients with Hidradenitis suppurativa (Hurley stages II-III)\n* Disease affecting at least two distinct anatomical areas,\n* Total count of abscesses (A) and inflammatory nodules (N) ≥ 3\n* IHS4 score ≥ 11\n* Treatment of pain with opioids (≥ 20 mg\u002Fday)\n* Resistance to previous use (for at least 3 months) of systemic antibiotics and TNF inhibitors (infliximab or adalimumab) or anti-IL17 (secukinumab).\n* Vaccinations against SARS-CoV-2 and influenza up to date (or able to be carried out prior to the study procedure)\n* Women using an effective method of contraception\n* Signed informed consent\n\nExclusion Criteria:\n\n* Active viral infection: herpes, VZV, HIV, HBV, HCV\n* Active bacterial infection requiring systemic antibiotics\n* Known allergy to blood components\u002Fplasma proteins\n* Poor myocardial function (increased risk of for transfusion-associated circulatory overload) (symptomatic left ventricular failure and ejection fraction \\\u003C 40%)\n* Pregnant women\n* Subjects with no social security coverage","ALL","18 Years",{"count":58,"type":59},6,"ESTIMATED","INTERVENTIONAL",[62],"PHASE1","The purpose of the study is to evaluate the safety and type 1 Interferon (IFN) neutralization in patients with refractory severe Hidradenitis Suppurativa (Hurley stage III) after transfusion of plasma containing high titer anti-IFN-1 autoantibodies.",[65],"Hidradenitis Suppurativa (HS)",[67,68],"Plasma therapy","Neutralizing type-1 interferon autoantibodies","NOT_YET_RECRUITING","2025-07-04",{"date":72,"type":73},"2025-07-16","ACTUAL",{"date":75,"type":59},"2025-09",{"date":77,"type":59},"2026-09",{"name":5,"class":6},1]